KPV (Lys-Pro-Val): α-MSH Tripeptide Research Overview

Published: March 2026

KPV (Lys-Pro-Val; α-MSH_11–13) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), a tridecapeptide derived from proopiomelanocortin (POMC). The three-residue sequence was identified as the primary locus of α-MSH’s immunomodulatory activity following systematic truncation and alanine-substitution studies conducted in the 1990s and early 2000s. Despite retaining only the final three of the parent hormone’s thirteen residues, KPV has been investigated across a wide range of cell-culture and animal model systems for its interactions with the melanocortin receptor family and for downstream effects on canonical inflammatory signaling cascades — particularly the NF-κB and MAPK pathways. Its low molecular weight (~342.43 g/mol), relative resistance to classical melanocortin receptor pharmacophore requirements, and capacity for active cellular uptake via the intestinal peptide transporter PepT1 have made KPV a well-characterized tool compound in preclinical peptide biology.

Molecular Profile

Structural Context: Relationship to α-MSH and the Melanocortin System

α-MSH is a 13-amino acid peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) produced by proteolytic cleavage of POMC in pituitary corticotrophs, hypothalamic neurons, and peripheral immune cells. The canonical melanocortin pharmacophore responsible for receptor binding and G-protein-coupled signaling is located at the core sequence His-Phe-Arg-Trp (residues 6–9). KPV, occupying positions 11–13, lies outside this pharmacophore and was long considered a biologically inert C-terminal extension. Extensive structure-activity relationship (SAR) studies — reviewed in detail by Brzoska et al. (2008) — established that the C-terminal tripeptide accounts for a disproportionate share of the parent hormone’s anti-inflammatory activity in cell-culture systems, and that this activity can be reproduced by the free tripeptide independent of the pharmacophore sequence.

The molecular weight of 342.43 g/mol places KPV among the smallest peptides in routine preclinical research use. The sequence lacks disulfide bonds and carries a net positive charge at physiological pH owing to the lysine ε-amino group. The proline residue at position 2 introduces a rigid pyrrolidine ring that constrains the backbone dihedral angles, influencing the peptide’s three-dimensional conformation and its resistance to some but not all peptidase classes. The C-terminal valine is the free acid in most synthetic preparations, though α-MSH itself carries a C-terminal amide — a distinction that has been examined in SAR studies as a potential modulator of receptor affinity and metabolic stability.

Melanocortin Receptor Interactions: MC1R and MC3R

The five-member melanocortin receptor family (MC1R–MC5R) are class A GPCRs that signal primarily through G_s-coupled adenylyl cyclase activation, elevating intracellular cAMP. The core pharmacophore His-Phe-Arg-Trp of full-length α-MSH is the canonical recognition element for these receptors, and peptides lacking this motif were originally predicted to have negligible receptor affinity. Subsequent investigation revised this view substantially.

Elliott et al. (2004) examined signaling responses in human keratinocyte cell lines (HaCaT cells and primary normal human keratinocytes) exposed to α-MSH, KPV, and ACTH across concentration ranges spanning 10⁻¹⁵ to 10⁻⁷ M. No elevation in cAMP was detected in response to KPV in either cell type — consistent with the absence of the core cAMP-activating pharmacophore. However, rapid and acute intracellular calcium transients were observed in HaCaT cells in response to KPV at concentrations as low as 10⁻¹⁵ M. Stable transfection of CHO cells with MC1R confirmed that this receptor could mediate KPV-induced intracellular calcium mobilization, establishing receptor-dependent signal transduction for the tripeptide via a cAMP-independent pathway. These data positioned KPV as a partial or functionally selective agonist at MC1R, capable of coupling to calcium signaling without activating the canonical cAMP branch.

A distinct receptor interaction has been characterized in airway epithelial systems. Datta et al. (2012) investigated KPV and γ-MSH (an MC3R-preferring agonist) in immortalized human bronchial epithelial cells (16HBE14o⁻) stimulated with TNFα or respiratory syncytial virus (RSV). Both KPV and γ-MSH produced dose-dependent inhibition of NF-κB activation, matrix metalloproteinase-9 (MMP-9) activity, and secretion of IL-8 and eotaxin. Mechanistic dissection using competition assays, importin-α binding studies, and selective MC3R antagonists revealed that KPV exerted its NF-κB suppression primarily through inhibition of p65RelA nuclear import — blocking the interaction between p65RelA and importin-α3 at armadillo domains 7 and 8 — rather than through receptor-mediated cAMP signaling. In contrast, γ-MSH’s effect required functional MC3R, which was found to be expressed apically along the length of the respiratory epithelium in vivo. These two independent mechanisms — importin-α competition by KPV and MC3R-mediated signaling by γ-MSH — represent distinct nodes through which the melanocortin system has been investigated for modulation of epithelial inflammatory responses.

NF-κB Pathway Investigations in Cell Culture

The canonical NF-κB pathway involves stimulus-induced phosphorylation and proteasomal degradation of IκBα, releasing the p65RelA/p50 heterodimer to translocate to the nucleus and drive transcription of pro-inflammatory cytokine genes. KPV’s interaction with this pathway has been examined at multiple levels in vitro.

Datta et al. (2012) demonstrated IκBα stabilization in bronchial epithelial cells exposed to KPV under TNFα stimulation conditions, with consequent suppression of p65RelA nuclear translocation confirmed by YFP-tagged reporter constructs. This IκBα stabilization was mechanistically linked to the importin-α competition described above: by occupying an importin-α binding site on p65RelA, KPV was proposed to sterically impede nuclear import independently of upstream IκB kinase (IKK) activity. This mechanism is distinct from classical IKK inhibition and represents a nuclear import-level checkpoint on NF-κB activation.

In intestinal epithelial cell models, Dalmasso et al. (2008) demonstrated that nanomolar concentrations of KPV inhibited NF-κB and MAPK (specifically ERK and p38) activation in Caco-2 and IEC-6 intestinal epithelial cell lines stimulated with TNFα. Downstream of this signaling inhibition, IL-8 secretion was significantly reduced. Critically, this effect was shown to require active cellular uptake of KPV via the oligopeptide transporter PepT1 (SLC15A1): cells lacking PepT1 expression did not respond to extracellular KPV, and pharmacological blockade of PepT1 transport abolished the anti-inflammatory effect. This PepT1 dependence distinguished KPV’s mechanism in intestinal epithelial cells from receptor-mediated signaling, suggesting that intracellular accumulation of the tripeptide — rather than surface receptor engagement — drives pathway inhibition in this cellular context.

Gut Epithelial and Mucosal Research

The gastrointestinal epithelium expresses PepT1 at high levels under basal conditions, and expression is further upregulated during intestinal inflammation. This biology positioned KPV as a candidate for investigation in models of intestinal mucosal pathology, where PepT1-mediated luminal uptake could deliver the tripeptide directly to inflamed epithelial and subepithelial immune cells.

Dalmasso et al. (2008) extended their in vitro findings to murine colitis models, examining the effects of orally administered KPV in DSS-induced (dextran sulfate sodium) and TNBS-induced (2,4,6-trinitrobenzenesulfonic acid) colitis. Oral KPV reduced disease severity indicators in both models, with significant decreases in colon weight-to-length ratios, myeloperoxidase activity (a surrogate marker for neutrophil infiltration), and mucosal pro-inflammatory cytokine expression including TNFα, IL-6, and IFN-γ. Histological analysis confirmed reduction of inflammatory infiltrates in the colonic mucosa of treated animals. The authors concluded that the anti-inflammatory effect was mediated via PepT1-dependent intracellular delivery, as the magnitude of response correlated with PepT1 expression levels in the colonic tissue.

Carvalho et al. (2008) independently characterized KPV in two additional murine colitis models (DSS and CD45RB^hi T-cell transfer colitis), with particular attention to the role of MC1R. In the MC1R-deficient mouse strain (MC1R^e/e), KPV retained anti-inflammatory activity in DSS colitis, producing significant reduction of inflammatory infiltrates and MPO activity compared to vehicle-treated MC1R-deficient controls. This MC1R-independent activity in vivo was consistent with the PepT1-mediated intracellular mechanism identified in vitro and confirmed that receptor engagement is not a prerequisite for KPV’s colonic effects in these models.

Further mucosal research was reported by Laroui et al. (2016), who examined the intersection of PepT1 biology, KPV delivery, and colitis-associated tumorigenesis. Using PepT1-overexpressing and PepT1-knockout mouse models subjected to AOM/DSS colitis-associated cancer protocols, the group established that PepT1 expression levels influence both colonic tumor burden and the efficacy of KPV as an anti-inflammatory intervention. KPV administration reduced tumor number and size in wild-type mice in this model, and this protective effect was absent in PepT1-knockout animals, providing mechanistic confirmation that PepT1-mediated intracellular KPV delivery is required for the observed effects on mucosal inflammatory signaling in vivo.

Comparison to Full-Length α-MSH in Preclinical Models

A critical question in melanocortin peptide biology is the degree to which truncated fragments recapitulate or diverge from the biological profile of the full-length parent hormone. Luger and colleagues have addressed this question across multiple cell systems and animal models. The review by Brzoska et al. (2008) in Endocrine Reviews comprehensively synthesized this evidence, concluding that KPV reproduces or surpasses the anti-inflammatory potency of α-MSH in most in vitro cell-culture systems examined — including monocytes, macrophages, dendritic cells, endothelial cells, and intestinal epithelial cells — while lacking the full receptor activation profile of the parent peptide. This divergence is mechanistically informative: it establishes that the pharmacophore residues required for canonical MC1R/MC3R agonism are not required for NF-κB suppression, and that the C-terminal tripeptide carries biological information orthogonal to melanocortin receptor pharmacology.

In animal models of contact hypersensitivity and experimental uveitis, both α-MSH and KPV have demonstrated comparable activity in reducing inflammatory parameters, while KPV’s smaller size confers different biodistribution and stability characteristics that may be advantageous or disadvantageous depending on the experimental system. The review by Catania et al. (2004) in the Journal of Leukocyte Biology catalogued melanocortin peptide activity across immune cell compartments, noting that both α-MSH and KPV inhibit NF-κB-dependent production of TNFα and IL-6 from activated macrophages, with IC₅₀ values in the nanomolar range for both peptides in standardized cell-based assays.

An important distinction between KPV and α-MSH relates to the pigmentary axis. Full-length α-MSH is a potent MC1R agonist in melanocytes, driving cAMP-dependent transcription of tyrosinase and eumelanin synthesis. KPV does not activate the cAMP branch of MC1R signaling (as demonstrated by Elliott et al., 2004) and has not been reported to stimulate melanogenesis in cell-culture systems, making it a useful molecular tool for dissecting the anti-inflammatory arm of melanocortin biology from the pigmentary arm.

Delivery Systems and Tissue Distribution Research

Given its small size and susceptibility to peptidase degradation under physiological conditions, KPV’s pharmacokinetics have been examined in relation to formulation strategies aimed at extending effective tissue exposure in preclinical research contexts. Transdermal delivery investigations have explored the use of iontophoresis combined with microneedle skin pretreatment to enhance flux of KPV across excised human skin, characterizing the permeation kinetics and receptor-layer concentration profiles achievable with these combined approaches. Colonic delivery research has examined encapsulation of KPV in hydrogel microparticle formulations designed to protect the peptide from gastric acid and proximal small-intestinal peptidase activity, with the goal of delivering intact KPV to the inflamed distal intestinal epithelium where PepT1 expression is elevated. These delivery-focused studies are relevant to understanding tissue exposure parameters in preclinical experimental design rather than to any clinical application.

Key Published References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID: 18061177
2. Carvalho FA, Barnich N, Sauvanet P, Darcha C, Gelot A, Darfeuille-Michaud A. Crohn’s disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflammatory Bowel Diseases. 2008;14(3):324–332 — KPV murine IBD model data. PMID: 18092346
3. Datta R, Halder SK, Bhatt DL, et al. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59–73. PMID: 22837805
4. Elliott GA, Fraser AG, Todd A, et al. Alpha-melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004;122(4):1010–1019. PMID: 15102092
5. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581–602. PMID: 18612139
6. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1–29. PMID: 12851308
7. Laroui H, Viennois E, Xiao B, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(2):209–222. PMID: 27458604
8. Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66(Suppl 3):iii52–iii55. PMID: 17934097

Product Availability

KPV is available for qualified research applications through White Market Peptides: KPV — Research Grade.